Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
New data highlights include:
- Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH
- Initial findings from research on comorbidities associated with adult growth hormone deficiency
“The flow of data that begins today at the PES annual meeting signifies the growing strength and breadth of our endocrinology rare disease portfolio,” said
Ascendis Pharma’s data and research presentations during the month of May are listed below. Registered attendees can find out more details at each event’s website.
PES 2022 Pediatric Endocrinology Society Virtual |
Oral Presentation Lonapegsomatropin in Children with Growth Hormone Deficiency: Efficacy & Safety After 2.5 years in the enliGHten Trial An analysis of the subset of participants who completed the trial, with information on difference between last visit height and target height, and difference between height SDS at last visit and average parental height SDS Virtual event; recorded, with Live Q&A |
|
ECTS 2022 European Calcified |
Oral Presentation Sustained Efficacy and Safety with TransCon PTH for Adults with Hypoparathyroidism Through Week 84 in the Phase 2 PaTH Forward Trial An evaluation of data at Week 84 in the PaTH Forward trial of TransCon PTH in adults with hypoparathyroidism showed 93% of participants achieving continued independence from conventional therapy with maintenance of mean serum calcium (sCa) and 24-hour urinary calcium (uCa) in the normal range. Date & time to be announced |
|
PENS 2022 |
Oral Presentation Continued Efficacy and Safety after 2.5 Years of Treatment with Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency in the enliGHten trial Data from Week 130 of the enliGHten trial reporting consistent long-term safety and sustained growth in pediatric growth hormone-deficient patients treated for 2.5 years with TransCon hGH. Also includes outcomes from auto-injector device usability questionnaire. Date and time to be announced. |
|
ECE 2022 & Virtual |
Oral Presentation Health Related Quality of Life in Adults with Hypoparathyroidism in the Phase 2 Path Forward Trial of TransCon PTH An analysis of patient-reported health and quality-of-life impacts from the SF-36® and Hypoparathyroidism Patient Experience Scale (HPES) – Symptom tools during the Phase 2 Path Forward Study of TransCon PTH in adult hypoparathyroidism. Recorded, with Live Q&A Dates and times to be announced. Poster Prevalence of Comorbidities in a An analysis of the comorbidity burden in adult patients diagnosed with growth hormone deficiency (GHD) compared to non-GHD controls. |
|
About
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers and distributors to supply TransCon hGH, the SKYTROFA® Auto-Injector and other study drug for commercial sales in the
Ascendis,
Investor Contacts: | Media Contact: | |
|
|
|
|
|
|
+1 (650) 374-6343 | +1 (650) 709-8875 | |
tle@ascendispharma.com | media@ascendispharma.com | |
|
||
ICR Westwicke | ||
+1 (415) 513-1284 | ||
patti.bank@westwicke.com | ||
ir@ascendispharma.com |
Source: Ascendis Pharma